Company intelligence / Profile preview
Gate Neurosciences
- Ownership
- Private
- Employees
- ~12
- Development stage
- Phase 2
Overview
Gate Neurosciences has advanced its lead candidate, zelquistinel—a once-weekly oral medicine targeting synaptic function—into Phase 2 trials for depression. The therapy aims to provide rapid symptom relief compared to traditional antidepressants. The company leverages a precision medicine approach using objective biomarkers and advanced analytics to optimize patient selection and outcomes. Additional pipeline details are limited but include other differentiated mechanisms for neuropsychiatric and cognitive disorders.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (e.g., zelquistinel)Precision neuroscience tools/biomarker-driven approaches
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Gate Neurosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gate Neurosciences.